Contact Urticaria Across Three Large Clinical Cohorts

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional workplace scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

What did the study actually examine?

What does the result mean?

Contact urticaria was diagnosed in 448 IVDK patients (0.28%) and 16 allergy-unit patients (0.34%); 19 severe workplace reactions with skin symptoms were identified in the anaphylaxis registry.

The denominator matters. Some papers began with an entire workforce, while others included only referred patients, accepted compensation claims or people selected for patch testing. A percentage from one of those groups cannot automatically be applied to everyone in the occupation.

It also helps to separate a symptom report, a clinician-confirmed dermatitis diagnosis and a positive allergy test. They are not interchangeable. A patch-test reaction indicates sensitization under test conditions; occupational relevance still depends on the exposure history, clinical pattern and timing.

What are the most important limitations?

The three cohorts used different inclusion rules and cannot be pooled as one prevalence estimate. Clinic and registry capture depends on recognition, referral and reporting.

Funding or conflicts were not fully stated in the PubMed abstract. Absence of a funding statement in an abstract is not proof that no funding or competing interest existed; it means the accessible record did not provide enough detail to make a stronger claim.

What can a worker document before an appointment?

• The exact task, material, cleanser, glove, resin, dye, metal, food, dust or equipment used.
• Where symptoms appear, when they begin, and whether they change on days away.
• Product labels and safety data—without placing workplace substances directly on the skin.
• Required PPE, handwashing frequency, heat, friction, sweating and wet-work duration.
• Changes in function, sleep, attendance or the ability to complete specific tasks.

Exposure controls, substitution, engineering measures and correctly selected protective equipment belong in the conversation with occupational health and the employer. Skin-care products do not replace those controls. Seek prompt medical care for severe pain, rapidly spreading redness, drainage, fever, breathing symptoms or major loss of function.

Primary research and guidance

• Primary research record: PubMed PMID 31173644
• NIOSH: occupational skin exposure
• NIAMS: atopic dermatitis overview
• American Academy of Dermatology: eczema skin care

PubMed indexing is not NIH endorsement of the study’s interpretation, this article or any product.

Where a cosmetic moisturizer fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine. This article makes no treatment, cure, prevention, itch-relief, pediatric-safety, universal-tolerance or 24-hour claim.

Bottom line

This evidence is most useful when its population, denominator and design travel with the number. Use it to sharpen questions about diagnosis, exposure and work design—not to promise that one routine works for every person or job.